The PACIFIC trial assesses the use of Durvalumab after chemotherapy in stage III NSCLC, with significant improvements in OS [90] The soon to be published ADAURA trial obtained unprecedented results with osimertinib in EGFR-positive NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.